Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1690 in Healthy Male Subjects

Trial Profile

Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1690 in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2016

At a glance

  • Drugs GLPG 1690 (Primary)
  • Indications Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors Galapagos NV
  • Most Recent Events

    • 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
    • 22 Sep 2015 According to a Galapagos media release, top-line data from this study will be presented at the European Respiratory Society Annual Meeting 2015.
    • 22 Sep 2015 Results published in a Galapagos media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top